Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Furong effervescent suppository versus clindamycin vaginal cream for bacterial vaginosis with aerobic vaginitis
ChiCTR1900027616Phase 4Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Jul 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Compound Furong in bacterial vaginosis (BV) and Aerobic Vaginitis (AV) (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Disease recovery rate. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
Compound Furong
03
Conditions
bacterial vaginosis (BV)Aerobic Vaginitis (AV)
Beyond the preview
Go deeper on ChiCTR1900027616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027616.